# Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

> **NCT04371978** · PHASE3 · TERMINATED · sponsor: **Rabin Medical Center** · enrollment: 64 (actual)

## Conditions studied

- COVID 19
- Coronavirus
- Diabetes Mellitus, Type 2
- Diabetes Mellitus
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases
- Dipeptidyl-Peptidase IV Inhibitors
- Linagliptin
- Severe Acute Respiratory Syndrome Coronavirus 2
- Sars-CoV2
- Hypoglycemic Agents
- Respiratory Tract Diseases
- Incretins
- Hormones

## Interventions

- **DRUG:** Linagliptin 5 MG

## Key facts

- **NCT ID:** NCT04371978
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-04-04
- **Final completion:** 2021-05-04
- **Target enrollment:** 64 (ACTUAL)
- **Why stopped:** End of COVID-19 outbreak in Israel
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371978, "Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04371978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*